Plain-English translation of NCT07052214 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new imaging scan called PSMA PET (combined with MRI) to see if it can better detect prostate cancer than current standard methods. The scan uses a special radioactive tracer called Gallium Ga 68 Gozetotide that is injected into your bloodstream to help doctors see cancer cells more clearly. Researchers want to understand whether this new imaging approach can help catch prostate cancer earlier and more accurately.
Many men with signs of prostate cancer need biopsies to confirm whether they actually have cancer, but current imaging methods are not always accurate. This trial is trying to find out whether the new imaging medication can better identify which men truly need a biopsy, potentially sparing some men from unnecessary procedures.
If you qualify, you will first have an MRI scan and the new PSMA PET scan with the radioactive tracer. After these scans, your doctor may perform a prostate biopsy (a tissue sample) based on what the scans show—or they may decide a biopsy isn't needed. You'll have a follow-up visit at 6 months to check how you're doing. The entire study takes about 6 months, with most of the active testing happening at the beginning.
AI-generated summary from trial data · Aug 12, 2026 · Not medical advice
United States